

SPECIFICATION AMENDMENTS

Please amend page 6, line 31 to page 7, line 1 to read as follows:

According to the present invention this object is solved by a method according to claim 1 and a medicament according to claims 16 to 18 using specific DNAzymes according to claims 10 to 15 the present invention as defined herein after.

Please insert the following on page 7, following line 1:

The invention relates to a DNAzyme which binds to GATA-3 mRNA and functionally inactivates it, which comprises:

- a catalytic domain with the nucleotide sequence GGCTAGCTAACACGA SEQ ID NO: 154 or a modified sequence with comparable biological effect, which cleaves the GATA-3 mRNA at every purine:pyrimidine binding site to which it is bonded,

- a right substrate binding domain adjoining the 3' end of the catalytic domain having polynucleotide sequence GTCTTGGAG and

- a left substrate binding domain adjoining the 5' end of the catalytic domain having polynucleotide sequence GTGGGATGGA, both substrate binding domains being respectively complementary to two regions of the GATA 3 mRNA so that they hybridize with the mRNA, and

- which is active in vivo.

In a preferred feature of the invention, the DNAzyme comprises sequence hqd 40 GTGGATGGA GGCTAGCTACAAACGA GTCTTGGAG which is SEQ ID NO: 40.

In particular the invention relates to a DNAzyme which cleaves the catalytic domain of the GATA-3 mRNA at every purine:uracil binding site.

Furthermore the DNAzyme according to the present invention is stabilized against decomposition within the organism by introduction of a 3'-3' inversion.

Another preferred feature of the invention relates to a DNAzyme which is stabilized against decomposition within the organism by introduction of modified nucleotides or nucleotide compounds.

A particular feature of the invention relates to a DNAzyme which includes an inverse thymidine on the 3' end and/or a FAM label on the 5' end.

The invention also relates to A medicament containing a DNAzyme according to the present invention and a pharmaceutically acceptable carrier.

Please amend page 7, following line 17 to insert the following:

Brief Description of the Drawings.